The trajectory of Sildenafil presents a complex case for observers in the pharmaceutical sector. While initially a phenomenal success, creating huge profits, the patent end and the subsequent arrival of off-brand versions have significantly changed income. This raises questions about the future profitability of analogous medication developments and